Isolated splenic metastasis in a patient with two distinct genitourinary malignancies

Article Type
Changed
Wed, 05/26/2021 - 13:56
Display Headline
Isolated splenic metastasis in a patient with two distinct genitourinary malignancies
Splenic metastasis is rare, occurring in 2.3%- 7.1% of cases, of which 95% are carcinomas.1 The lung is the most common primary tumor site (21% of cases), followed by the gastrointestinal system, breast, ovaries, and skin. In a retrospective study evaluating the clinical and pathological impact of splenic metastases during a 25-year period in China, it was found that about 5.3% of metastases were isolated splenic metastasis.2  Isolated splenic metastasis from kidney cancer is very rare and is often an incidental finding. Here we report a case with isolated splenic metastasis in a patient with both primary renal cell carcinoma and prostate cancer, which turned out to be metastatic renal cell carcinoma in the spleen.  

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(6)
Publications
Topics
Page Number
229-230
Legacy Keywords
splenic metastasis, renal cell carcinoma, prostate cancer, metastatic renal cell carcinoma, spleen
Sections
Article PDF
Article PDF
Splenic metastasis is rare, occurring in 2.3%- 7.1% of cases, of which 95% are carcinomas.1 The lung is the most common primary tumor site (21% of cases), followed by the gastrointestinal system, breast, ovaries, and skin. In a retrospective study evaluating the clinical and pathological impact of splenic metastases during a 25-year period in China, it was found that about 5.3% of metastases were isolated splenic metastasis.2  Isolated splenic metastasis from kidney cancer is very rare and is often an incidental finding. Here we report a case with isolated splenic metastasis in a patient with both primary renal cell carcinoma and prostate cancer, which turned out to be metastatic renal cell carcinoma in the spleen.  

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Splenic metastasis is rare, occurring in 2.3%- 7.1% of cases, of which 95% are carcinomas.1 The lung is the most common primary tumor site (21% of cases), followed by the gastrointestinal system, breast, ovaries, and skin. In a retrospective study evaluating the clinical and pathological impact of splenic metastases during a 25-year period in China, it was found that about 5.3% of metastases were isolated splenic metastasis.2  Isolated splenic metastasis from kidney cancer is very rare and is often an incidental finding. Here we report a case with isolated splenic metastasis in a patient with both primary renal cell carcinoma and prostate cancer, which turned out to be metastatic renal cell carcinoma in the spleen.  

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Issue
The Journal of Community and Supportive Oncology - 13(6)
Issue
The Journal of Community and Supportive Oncology - 13(6)
Page Number
229-230
Page Number
229-230
Publications
Publications
Topics
Article Type
Display Headline
Isolated splenic metastasis in a patient with two distinct genitourinary malignancies
Display Headline
Isolated splenic metastasis in a patient with two distinct genitourinary malignancies
Legacy Keywords
splenic metastasis, renal cell carcinoma, prostate cancer, metastatic renal cell carcinoma, spleen
Legacy Keywords
splenic metastasis, renal cell carcinoma, prostate cancer, metastatic renal cell carcinoma, spleen
Sections
Citation Override
JCSO 2015;13:229-230
Disallow All Ads
Alternative CME
Article PDF Media

Gemicitabine-induced radiation recall phenomenon in 2 distinctive sites on the same patient

Article Type
Changed
Fri, 01/04/2019 - 11:09
Display Headline
Gemicitabine-induced radiation recall phenomenon in 2 distinctive sites on the same patient

Radiation recall phenomenon is an acute inflammatory reaction that develops in previously irradiated areas after administration of inciting agents systemically. The most common agents are anticancer drugs.1 Gemcitabine, a fluorine-substituted deoxycytidine analog, is widely used as a chemotherapy medication. Its antitumor effect results from the blockade of DNA synthesis and DNA repair. It has been used in advanced pancreatic, non–small-cell lung, bladder, and ovarian cancers; soft-tissue sarcoma; and non-Hodgkin lymphoma.2 It has occasionally been reported to cause radiation recall phenomenon.3 The time between radiation and recall may range from weeks to almost a year.
 

Click on the PDF icon at the top of this introduction to read the full article.

 

 

 

Article PDF
Author and Disclosure Information

 

 

Issue
The Journal of Community and Supportive Oncology - 12(5)
Publications
Topics
Page Number
188-190
Legacy Keywords
radiation recall phenomenon, gemcitabine, squamous cell carcinoma,
Sections
Author and Disclosure Information

 

 

Author and Disclosure Information

 

 

Article PDF
Article PDF

Radiation recall phenomenon is an acute inflammatory reaction that develops in previously irradiated areas after administration of inciting agents systemically. The most common agents are anticancer drugs.1 Gemcitabine, a fluorine-substituted deoxycytidine analog, is widely used as a chemotherapy medication. Its antitumor effect results from the blockade of DNA synthesis and DNA repair. It has been used in advanced pancreatic, non–small-cell lung, bladder, and ovarian cancers; soft-tissue sarcoma; and non-Hodgkin lymphoma.2 It has occasionally been reported to cause radiation recall phenomenon.3 The time between radiation and recall may range from weeks to almost a year.
 

Click on the PDF icon at the top of this introduction to read the full article.

 

 

 

Radiation recall phenomenon is an acute inflammatory reaction that develops in previously irradiated areas after administration of inciting agents systemically. The most common agents are anticancer drugs.1 Gemcitabine, a fluorine-substituted deoxycytidine analog, is widely used as a chemotherapy medication. Its antitumor effect results from the blockade of DNA synthesis and DNA repair. It has been used in advanced pancreatic, non–small-cell lung, bladder, and ovarian cancers; soft-tissue sarcoma; and non-Hodgkin lymphoma.2 It has occasionally been reported to cause radiation recall phenomenon.3 The time between radiation and recall may range from weeks to almost a year.
 

Click on the PDF icon at the top of this introduction to read the full article.

 

 

 

Issue
The Journal of Community and Supportive Oncology - 12(5)
Issue
The Journal of Community and Supportive Oncology - 12(5)
Page Number
188-190
Page Number
188-190
Publications
Publications
Topics
Article Type
Display Headline
Gemicitabine-induced radiation recall phenomenon in 2 distinctive sites on the same patient
Display Headline
Gemicitabine-induced radiation recall phenomenon in 2 distinctive sites on the same patient
Legacy Keywords
radiation recall phenomenon, gemcitabine, squamous cell carcinoma,
Legacy Keywords
radiation recall phenomenon, gemcitabine, squamous cell carcinoma,
Sections
Citation Override
JCSO 2014;12:188-190
Disallow All Ads
Alternative CME
Article PDF Media